Acetylon Pharma Raises $7.25 Million
Acetylon Pharmaceuticals Inc., a Cambridge, Mass.-based developer of HDAC inhibitor drug candidates, has raised $7.25 million in Series A funding. No investors were named, although VentureWire reports that the capital came from Kraft Group and individual angels.
7 August 2009•6 mins read
